Effect  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
oral  ||| S:10 E:15 ||| JJ
alkali  ||| S:15 E:22 ||| JJ
supplementation  ||| S:22 E:38 ||| NN
on  ||| S:38 E:41 ||| IN
progression  ||| S:41 E:53 ||| NN
of  ||| S:53 E:56 ||| IN
chronic  ||| S:56 E:64 ||| JJ
kidney  ||| S:64 E:71 ||| NN
disease  ||| S:71 E:79 ||| NN
Metabolic  ||| S:79 E:89 ||| NNP
acidosis  ||| S:89 E:98 ||| NN
is  ||| S:98 E:101 ||| VBZ
a  ||| S:101 E:103 ||| DT
frequent  ||| S:103 E:112 ||| JJ
but  ||| S:112 E:116 ||| CC
asymptomatic  ||| S:116 E:129 ||| JJ
complication  ||| S:129 E:142 ||| NN
in  ||| S:142 E:145 ||| IN
chronic  ||| S:145 E:153 ||| JJ
kidney  ||| S:153 E:160 ||| NN
disease  ||| S:160 E:168 ||| NN
( ||| S:168 E:169 ||| -LRB-
CKD ||| S:169 E:172 ||| NNP
) ||| S:172 E:173 ||| -RRB-
.  ||| S:173 E:175 ||| .
In  ||| S:175 E:178 ||| IN
early  ||| S:178 E:184 ||| JJ
stages  ||| S:184 E:191 ||| NNS
of  ||| S:191 E:194 ||| IN
CKD  ||| S:194 E:198 ||| NNP
acidosis  ||| S:198 E:207 ||| NN
is  ||| S:207 E:210 ||| VBZ
limited  ||| S:210 E:218 ||| VBN
to  ||| S:218 E:221 ||| TO
the  ||| S:221 E:225 ||| DT
renal  ||| S:225 E:231 ||| JJ
tissue  ||| S:231 E:238 ||| NN
and  ||| S:238 E:242 ||| CC
progresses  ||| S:242 E:253 ||| VBZ
to  ||| S:253 E:256 ||| TO
reduced  ||| S:256 E:264 ||| JJ
serum  ||| S:264 E:270 ||| JJ
bicarbonate  ||| S:270 E:282 ||| JJ
levels ||| S:282 E:288 ||| NNS
.  ||| S:288 E:290 ||| .
Reduced  ||| S:290 E:298 ||| VBN
renal  ||| S:298 E:304 ||| JJ
tissue  ||| S:304 E:311 ||| NN
pH  ||| S:311 E:314 ||| NN
and  ||| S:314 E:318 ||| CC
increased  ||| S:318 E:328 ||| JJ
ammoniagenesis  ||| S:328 E:343 ||| NNS
are  ||| S:343 E:347 ||| VBP
the  ||| S:347 E:351 ||| DT
key  ||| S:351 E:355 ||| JJ
mechanisms  ||| S:355 E:366 ||| NNS
of  ||| S:366 E:369 ||| IN
the  ||| S:369 E:373 ||| DT
kidney  ||| S:373 E:380 ||| NN
to  ||| S:380 E:383 ||| TO
enhance  ||| S:383 E:391 ||| VB
acid  ||| S:391 E:396 ||| JJ
excretion  ||| S:396 E:406 ||| NN
to  ||| S:406 E:409 ||| TO
the  ||| S:409 E:413 ||| DT
urine ||| S:413 E:418 ||| NN
.  ||| S:418 E:420 ||| .
The  ||| S:420 E:424 ||| DT
expressed  ||| S:424 E:434 ||| JJ
protein  ||| S:434 E:442 ||| NN
patterns  ||| S:442 E:451 ||| NNS
in  ||| S:451 E:454 ||| IN
the  ||| S:454 E:458 ||| DT
proximal  ||| S:458 E:467 ||| JJ
tubular  ||| S:467 E:475 ||| JJ
epithelial  ||| S:475 E:486 ||| JJ
cells  ||| S:486 E:492 ||| NNS
change  ||| S:492 E:499 ||| VBP
remarkably ||| S:499 E:509 ||| RB
,  ||| S:509 E:511 ||| ,
the  ||| S:511 E:515 ||| DT
proximal  ||| S:515 E:524 ||| FW
convoluted  ||| S:524 E:535 ||| FW
tubule  ||| S:535 E:542 ||| FW
develops  ||| S:542 E:551 ||| FW
hypertrophy ||| S:551 E:562 ||| FW
,  ||| S:562 E:564 ||| ,
and  ||| S:564 E:568 ||| CC
an  ||| S:568 E:571 ||| DT
intra-renal  ||| S:571 E:583 ||| JJ
enhanced  ||| S:583 E:592 ||| JJ
renin-angiotensin-system  ||| S:592 E:617 ||| NN
leads  ||| S:617 E:623 ||| VBZ
to  ||| S:623 E:626 ||| TO
interstitial  ||| S:626 E:639 ||| VB
fibrosis ||| S:639 E:647 ||| NNS
.  ||| S:647 E:649 ||| .
Since  ||| S:649 E:655 ||| IN
nephrons  ||| S:655 E:664 ||| NNS
are  ||| S:664 E:668 ||| VBP
numerically  ||| S:668 E:680 ||| RB
reduced  ||| S:680 E:688 ||| VBN
in  ||| S:688 E:691 ||| IN
CKD  ||| S:691 E:695 ||| NNP
each  ||| S:695 E:700 ||| DT
remaining  ||| S:700 E:710 ||| JJ
functional  ||| S:710 E:721 ||| JJ
unit  ||| S:721 E:726 ||| NN
has  ||| S:726 E:730 ||| VBZ
to  ||| S:730 E:733 ||| TO
progressively  ||| S:733 E:747 ||| RB
increase  ||| S:747 E:756 ||| VB
these  ||| S:756 E:762 ||| DT
mechanisms  ||| S:762 E:773 ||| NNS
to  ||| S:773 E:776 ||| TO
keep  ||| S:776 E:781 ||| VB
up  ||| S:781 E:784 ||| RP
the  ||| S:784 E:788 ||| DT
equilibrium ||| S:788 E:799 ||| NN
.  ||| S:799 E:801 ||| .
The  ||| S:801 E:805 ||| DT
adverse  ||| S:805 E:813 ||| JJ
effects  ||| S:813 E:821 ||| NNS
of  ||| S:821 E:824 ||| IN
chronic  ||| S:824 E:832 ||| JJ
metabolic  ||| S:832 E:842 ||| JJ
acidosis  ||| S:842 E:851 ||| NNS
include  ||| S:851 E:859 ||| VBP
aside  ||| S:859 E:865 ||| RB
from  ||| S:865 E:870 ||| IN
acceleration  ||| S:870 E:883 ||| NN
of  ||| S:883 E:886 ||| IN
progression  ||| S:886 E:898 ||| NN
of  ||| S:898 E:901 ||| IN
kidney  ||| S:901 E:908 ||| NN
disease ||| S:908 E:915 ||| NN
,  ||| S:915 E:917 ||| ,
the  ||| S:917 E:921 ||| DT
development  ||| S:921 E:933 ||| NN
or  ||| S:933 E:936 ||| CC
exacerbation  ||| S:936 E:949 ||| NN
of  ||| S:949 E:952 ||| IN
bone  ||| S:952 E:957 ||| NN
disease ||| S:957 E:964 ||| NN
,  ||| S:964 E:966 ||| ,
increased  ||| S:966 E:976 ||| VBD
degradation  ||| S:976 E:988 ||| VBN
of  ||| S:988 E:991 ||| IN
muscle  ||| S:991 E:998 ||| NN
with  ||| S:998 E:1003 ||| IN
muscle  ||| S:1003 E:1010 ||| NN
wasting ||| S:1010 E:1017 ||| NN
,  ||| S:1017 E:1019 ||| ,
enhanced  ||| S:1019 E:1028 ||| JJ
protein  ||| S:1028 E:1036 ||| NN
degradation  ||| S:1036 E:1048 ||| NN
and  ||| S:1048 E:1052 ||| CC
inflammation ||| S:1052 E:1064 ||| NN
.  ||| S:1064 E:1066 ||| .
Genome  ||| S:1066 E:1073 ||| JJ
wide  ||| S:1073 E:1078 ||| JJ
association  ||| S:1078 E:1090 ||| NN
studies  ||| S:1090 E:1098 ||| NNS
demonstrated  ||| S:1098 E:1111 ||| VBN
that  ||| S:1111 E:1116 ||| IN
tubular  ||| S:1116 E:1124 ||| JJ
acid-base  ||| S:1124 E:1134 ||| JJ
transporters  ||| S:1134 E:1147 ||| NNS
are  ||| S:1147 E:1151 ||| VBP
involved  ||| S:1151 E:1160 ||| VBN
in  ||| S:1160 E:1163 ||| IN
the  ||| S:1163 E:1167 ||| DT
development  ||| S:1167 E:1179 ||| NN
of  ||| S:1179 E:1182 ||| IN
arterial  ||| S:1182 E:1191 ||| JJ
hypertension ||| S:1191 E:1203 ||| NN
.  ||| S:1203 E:1205 ||| .
Several  ||| S:1205 E:1213 ||| JJ
retrospective  ||| S:1213 E:1227 ||| JJ
analyses  ||| S:1227 E:1236 ||| NNS
have  ||| S:1236 E:1241 ||| VBP
indicated  ||| S:1241 E:1251 ||| VBN
that  ||| S:1251 E:1256 ||| IN
low  ||| S:1256 E:1260 ||| JJ
serum  ||| S:1260 E:1266 ||| JJ
bicarbonate  ||| S:1266 E:1278 ||| NN
predicts  ||| S:1278 E:1287 ||| VBZ
death  ||| S:1287 E:1293 ||| NN
in  ||| S:1293 E:1296 ||| IN
cohorts  ||| S:1296 E:1304 ||| NNS
with  ||| S:1304 E:1309 ||| IN
CKD  ||| S:1309 E:1313 ||| NNP
and  ||| S:1313 E:1317 ||| CC
cardiovascular  ||| S:1317 E:1332 ||| JJ
disease ||| S:1332 E:1339 ||| NN
.  ||| S:1339 E:1341 ||| .
All  ||| S:1341 E:1345 ||| DT
studies  ||| S:1345 E:1353 ||| NNS
confirmed  ||| S:1353 E:1363 ||| VBD
a  ||| S:1363 E:1365 ||| DT
U-shaped  ||| S:1365 E:1374 ||| JJ
association  ||| S:1374 E:1386 ||| NN
of  ||| S:1386 E:1389 ||| IN
mortality  ||| S:1389 E:1399 ||| NN
and  ||| S:1399 E:1403 ||| CC
serum  ||| S:1403 E:1409 ||| JJ
bicarbonate ||| S:1409 E:1420 ||| NN
,  ||| S:1420 E:1422 ||| ,
indicating  ||| S:1422 E:1433 ||| VBG
that  ||| S:1433 E:1438 ||| IN
both ||| S:1438 E:1442 ||| DT
,  ||| S:1442 E:1444 ||| ,
acidosis  ||| S:1444 E:1453 ||| NN
and  ||| S:1453 E:1457 ||| CC
alkalosis  ||| S:1457 E:1467 ||| NNS
are  ||| S:1467 E:1471 ||| VBP
associated  ||| S:1471 E:1482 ||| VBN
with  ||| S:1482 E:1487 ||| IN
increased  ||| S:1487 E:1497 ||| JJ
mortality ||| S:1497 E:1506 ||| NN
.  ||| S:1506 E:1508 ||| .
Randomized  ||| S:1508 E:1519 ||| RB
controlled  ||| S:1519 E:1530 ||| VBN
trials  ||| S:1530 E:1537 ||| NNS
showed  ||| S:1537 E:1544 ||| VBD
that  ||| S:1544 E:1549 ||| DT
base  ||| S:1549 E:1554 ||| NN
substitution ||| S:1554 E:1566 ||| NN
,  ||| S:1566 E:1568 ||| ,
either  ||| S:1568 E:1575 ||| CC
by  ||| S:1575 E:1578 ||| IN
modification  ||| S:1578 E:1591 ||| NN
of  ||| S:1591 E:1594 ||| IN
the  ||| S:1594 E:1598 ||| DT
diet  ||| S:1598 E:1603 ||| NN
or  ||| S:1603 E:1606 ||| CC
by  ||| S:1606 E:1609 ||| IN
simply  ||| S:1609 E:1616 ||| RB
adding  ||| S:1616 E:1623 ||| VBG
alkalizing  ||| S:1623 E:1634 ||| JJ
agents ||| S:1634 E:1640 ||| NNS
,  ||| S:1640 E:1642 ||| ,
might  ||| S:1642 E:1648 ||| MD
halt  ||| S:1648 E:1653 ||| VB
the  ||| S:1653 E:1657 ||| DT
decline  ||| S:1657 E:1665 ||| NN
of  ||| S:1665 E:1668 ||| IN
kidney  ||| S:1668 E:1675 ||| NN
function  ||| S:1675 E:1684 ||| NN
in  ||| S:1684 E:1687 ||| IN
subjects  ||| S:1687 E:1696 ||| NNS
with  ||| S:1696 E:1701 ||| IN
CKD ||| S:1701 E:1704 ||| NNP
.  ||| S:1704 E:1706 ||| .
In  ||| S:1706 E:1709 ||| IN
2012  ||| S:1709 E:1714 ||| CD
a  ||| S:1714 E:1716 ||| DT
meta-analysis  ||| S:1716 E:1730 ||| NN
concluded  ||| S:1730 E:1740 ||| VBD
that  ||| S:1740 E:1745 ||| DT
alkali  ||| S:1745 E:1752 ||| JJ
therapy  ||| S:1752 E:1760 ||| NN
might  ||| S:1760 E:1766 ||| MD
provide  ||| S:1766 E:1774 ||| VB
a  ||| S:1774 E:1776 ||| DT
long-term  ||| S:1776 E:1786 ||| JJ
favorable  ||| S:1786 E:1796 ||| JJ
effect  ||| S:1796 E:1803 ||| NN
on  ||| S:1803 E:1806 ||| IN
renal  ||| S:1806 E:1812 ||| JJ
function  ||| S:1812 E:1821 ||| NN
in  ||| S:1821 E:1824 ||| IN
patients  ||| S:1824 E:1833 ||| NNS
with  ||| S:1833 E:1838 ||| IN
CKD ||| S:1838 E:1841 ||| NNP
.  ||| S:1841 E:1843 ||| .
